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Background: This study investigated the efficacy and safety of autologous bone marrow-mononuclear cells (ABMMNC)
implantation in patients with critical limb ischemia (CLI) due to thromboangiitis obliterans (Buerger’s disease).
Methods: The study comprised 28 patients (25 men and 3 women) with a median age of 44 years (range, 25-54 years) who
had thromboangiitis obliterans and unilateral critical limb ischemia, defined as ischemic rest pain in a limb with or
without nonhealing ulcers. The patients received multiple injections of erythrocyte-depleted and volume-reduced
ABMMNC into the gastrocnemius muscle, the intermetatarsal region, and the feet dorsum (n  26) or forearm (n  2)
vs saline injections into the less ischemic contralateral limbs. The patients were nonresponders to previous Iloprost
infusion and smoking cessation>6months andwere not candidates for nonsurgical or surgical revascularization. Primary
end points were the total healing of the most important lesion while avoiding major or minor amputation, the relief of
rest pain without the need for analgesics from baseline to 6 months’ follow-up, and the safety and feasibility of the
treatment. Secondary end points were the changes in ankle-brachial pressure index and peak walking time, the
angiographic evidence of collateral vessel formation or remodeling, and the quality-of-life assessment. Two investigators
blinded for treatment assignment performed image analyses.
Results: Unilateral intramuscular administration of ABMMNC was not associated with any complications. The mean
follow-up time was 16.6  7.8 months (range, 7.6 to 33.8 months). Only one patient required toe amputation during
follow-up. A change in the ankle-brachial pressure index>0.15 was achieved in 8 patients at 3 months and in 14 patients
at 6 months compared with baseline values. At 6 months, patients demonstrated a significant improvement in rest pain
scores (P < .0001), peak walking time (P < .0001), and quality of life (P < .0083). Total healing of the most important
lesion was achieved in 15 patients (83%) with ischemic ulcers, and relief of rest pain without the need of narcotic analgesics
improved in all patients. Digital subtraction angiography studies before and 6 months after the ABMMNC implantation
showed vascular collateral networks had formed across the affected arteries in 22 patients (78.5%).
Conclusions: ABMMNC implantation could be a safe alternative to achieve therapeutic angiogenesis in patients
with thromboangiitis obliterans and critical limb ischemia refractory to other treatment modalities. ( J Vasc Surg 2006;
44:732-9.)Since the first detailed and accurate description by Leo
Buerger in 1908, the cause of thromboangiitis obliterans
(TAO, Buerger’s disease) has remained unknown, and the
treatment modalities have been unsatisfactory in this type
of nonatherosclerotic, segmental, inflammatory vasculitis.
The only way to prevent the progression of the disease is to
abstain from all tobacco products; otherwise, the disease
spontaneously leads to tissue loss and major amputations.
Patients may continue to have claudication or Raynaud’s
phenomenon even after the complete discontinuation of
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732tobacco use, however.1 The effectiveness of surgical sym-
pathectomy remains unclear.2 Revascularization is fre-
quently not feasible because of the diffuse segmental in-
volvement and distal nature of the disease. Therapeutic
angiogenesis by using cellular therapeutic strategies may be
useful in these patients.3
Bone marrow–derived endothelial progenitor cells
(EPCs) or angioblasts isolated from peripheral blood
were shown to have incorporated into the sites of active
angiogenesis and were identified as a key factor for
re-endothelialization.4 EPCs contribute to tissue vascular-
ization during embryonic and postnatal physiologic pro-
cesses.5,6 Recent findings suggest that growth and devel-
opment of new blood vessels in the adult are not restricted
to angiogenesis but encompass vasculogenesis as well.7,8
In a clinical setting, Tateishi-Yuyama et al9 have re-
cently established that implantation of autologous bone
marrow-mononuclear cells (ABMMNC), including EPCs,
into ischemic limbs increases collateral vessel formation.9
In addition, recent publications have described beneficial
effects of ABMMNC10,11 and autologous peripheral blood
mononuclear cells (APBMNC)12-15 in the setting of critical
limb ischemia (CLI) in humans. The aim of this study,
lear ce
ID, no
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Volume 44, Number 4 Durdu et al 733therefore, was to evaluate the feasibility, safety, reproduc-
ibility, and efficacy of ABMMNC implantation in patients
with CLI due to TAO.
METHODS
Patient population. Between April 2003 and August
2005, 28 consecutive patients diagnosed with TAO graded
II or III according to the recommended classification by
Rutherford et al,16 who were not candidates for conven-
tional forms of revascularization, were included in the
study. The clinical characteristics of the study group are
reported in the Table.
Definitions. TAO was diagnosed by using the clinical
criteria previously defined by Shionoya17 and modified by
Olin,1 including (1) smoking history, (2) age of onset 45
years, (3) infrapopliteal arterial occlusive disease docu-
mented by noninvasive vascular testing, (4) objective evi-
dence of medium or small arterial disease by angiography,
(5) upper limb involvement or phlebitis migrans, (6) ab-
sence of atherosclerotic risk factors other than smoking at
Table. Demographic characteristics, presenting symptoms
obliterans who received implantation of autologous bone m
Variable
Mean age  SD (range)
Gender (M/F)
Duration between diagnosis and ABMMNC implantatio
yrs mean  SD (range)
Hypertension
Hyperlipidemia
Previous smoking
History of intermittent claudication
Pain at rest (narcotic requirement)
Ischemic nonhealing ulcer
Thrombophlebitis
Raynaud’s phenomenon
Sensorial findings
Abnormal Allen’s test result
Upper extremity involvement by DSA
Previous ethanol abuse
Previous treatments
Hyperbaric oxygen
Sympathectomy
Sympathetic nerve block
Previous amputation
Major/minor
Distal bypass graft
Below knee/crural arteries
Previous infusion of iloprost
Medications on initial consultation
ACE-inhibitor/ARB
Statin
ASA/clopidogrel
Pentoxifylline
Calcium channel blocker
Cilostazol
NSAID
Morphine
SD, Standard deviation; ABMMNC, autologous bone-marrow mononuc
enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; NSAthe time of initial diagnosis, (7) exclusion of autoimmunediseases, diabetes mellitus, proximal source of emboli, and
hypercoagulable states.
Inclusion criteria were (1) unilateral CLI, defined as
ischemic rest pain in a limb with or without nonhealing
ulcers, (2) unresponsive clinical condition to smoking ces-
sation 6 months before ABMMNC implantation, (3) un-
responsive clinical condition to previous intravenous infu-
sion of iloprost, (4) unsuitable vessel lesions for nonsurgical
or surgical revascularization, (5) unhealed trophic lesions
despite intensive wound care for 6 months for patients
presented with ischemic ulcers, and (6) signed, informed
consent.
Patients were not enrolled in the study if any of the
following exclusion criteria were met: (1) concomitant
cause for arterial occlusive disease, including diabetes mel-
litus, atherosclerosis, connective tissue, or thrombotic dis-
eases; (2) detection of proximal source of emboli including
atrial fibrillation; (3) previous or current history of neopla-
sia or other comorbidity that could impact the patient’s
survival; (4) primary hematologic disease, including hyper-
signs of patient population with thromboangitis
w-derived mononuclear cells
n %
42.6  7.9 (25-56)
25/3
9.5  4.8 (1-23)
3 10.7
3 10.7
28 100
26 92.8
23 82.1
18 64.3
18 64.3
11 39.2
21 75
14 50
9 32.1
8 28.6
13 46.4
17 60.7
9 32.1
12 42.8
2/10 7.1/35.7
2 7.1
1/1 3.6/3.6
5 17.8
1 3.6
3 10.7
22 78.6
26 92.8
19 67.8
1 3.6
20 71.4
14 50
lls; DSA, digital subtraction angiography; ACE, angiotensin converting
nsteroidal anti-inflammatory drug.and
arro
n,coagulable states; (5) detection of proliferative retinopathy;
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(8) current ethanol abuse or cocaine, amphetamine, and
cannabis ingestion; and (9) detection of osteomyelitis.
The Research Ethics and Scientific Committee of the
Medical Faculty, University of Ankara, approved the study
protocol and all subjects gave informed consent.
Baseline evaluation. On admission, complete labora-
tory tests and serologic profile were obtained for all pa-
tients, including complete blood count with differential,
liver function, renal function, fasting blood glucose, urine
analysis, erythrocyte sedimentation rate, C-reactive protein,
antinuclear antibody, rheumatoid factor, anticentromere
antibody, antiphospholipid antibodies, Scl-70, fibrinogen,
complement measurements, serum homocysteine, hyper-
coagulability screen (protein C, protein S, and antithrom-
bin III plasma levels, and factor V Leiden, and prothrombin
20210A genemutation analysis), chest radiograph, electro-
cardiogram, and transthoracic echocardiography. Safety
was evaluated in the study by adverse event monitoring,
physical examinations, laboratory tests, resting electrocar-
diograms, and ophthalmologic examinations. All the pa-
tients underwent a routine preharvest examination and
work-up by an experienced hematologist from the Stem
Cell Transplantation Unit. Aspirin and clopidogrel were
discontinued 5 to 7 days before ABMMNC implantation.
All patients underwent a standard vascular examination
that includedmeasurement of ankle-brachial pressure index
(ABPI) assessed with duplex ultrasonography. They under-
went a validated progressive treadmill protocol, with a
reduced initial speed (1.6 km/h),18 in which they contin-
ued walking until they reached claudication pain or another
clinical indication for stopping the test. Claudication onset
time, claudication distance, peak walking time, and distance
were recorded. Those who previously had below-knee am-
putation were asked to walk with their prosthesis at a
self-selected velocity over an increasing walking distance. A
10-cm visual analog scale (VAS) was recorded monthly by
the patients for pain, where 0 was no pain at all and 10 was
the most severe pain ever experienced for ischemic and
control limbs.
Appropriate systemic antibiotic therapywas prescribed for
patients with trophic ulcers as determined by microbiologic
quantitative tissue cultures and sensitivity results. Before the
patient was considered for cellular therapy, local wound care
and surgical débridement were applied until three-culture
negative microbiologic results were achieved. Ischemic ulcers
were documented by digital color photography.
Intra-arterial digital subtraction angiography.
Digital subtraction angiography (DSA) (Multistar Plus/
T.O.P., Siemens AG, Forchheim, Germany) of both upper
and lower extremities was performed for all patients at
baseline and at the 6-month follow-up. The amount and
the force of low-osmolality nonionic contrast injection and
the position of the catheter tip (5F, Weinberg, pigtail,
Digiflex, Boston Scientific Corp, Watertown, Mass) was
strictly fixed for DSA studies to obtain identical imaging
conditions.To evaluate proximal vasculature, contrast media injec-
tion doses were as follows: 2 frames/s per 2 mL (total dose,
4 mL) for the superficial femoral artery, 2 frames/s per
/3 mL (total dose, 6 mL) for the popliteal artery, 2
frames/s per 4 mL (total dose, 8 mL) above the knee, and
2 frames/s per 5 mL (total dose, 10 mL) distal to the knee.
For evaluation, each leg was divided into 14 segments.
Angiographic mapping of both lower limbs and com-
parison of all the evaluated segments were reviewed by two
independent radiologists blinded to the treated extremity.
The angiographic scores for the formation of new collateral
vessel formation were assessed as 0 (no collateral devel-
opment), 1 (slight), 2 (moderate), and 3 (rich), as
described previously.9
Vascular Quality of Life Questionnaire. The King’s
College Hospital’s Vascular Quality of Life Questionnaire
(VascuQol) was used to assess QOL at baseline, and at 3
and 6 months after the procedure.19 The 25-item question-
naire was related to pain, other symptoms, activity, social,
and emotional items. The total VascuQol score was also
scored 1 to 7 (all the item scores divided by 25) for each
evaluation.
Bone marrow harvest and isolation of mononuclear
cells. The stem cell transplantation team collected bone
marrow from both spina iliaca posterior superior at prone
position under general anesthesia approximately 2 hours
before the ABMMNC implantation. The collected bone
marrow (653.2 77.3 mL) was immediately transferred to
the Hemapheresis Unit. Using this schedule, we targeted
total mononuclear cells of 1  10e8-9/mL while avoiding
unnecessary red blood cell (RBC) implantation and higher
harvest volumes. The harvest material was processed on
COBE Spectra (Gambro BCT, Lakewood, Colo) using the
bonemarrow processing program and software version 5.1.
After RBC depletion and volume reduction using a
continuous flow cell separator in a closed system,20 we
achieved 91%  2% RBC depletion and concentrated
ABMMNC to a final volume and concentration of 59.9 
9.2 mL and 1.69  0.89  10e9/mL total mononuclear
cells, respectively. The total number of implanted CD34
cells was 53.1  35.9  10e6. Cytofluorimetric analysis of
implanted stem cells was 99% viable and included 97.5 
2.2 percentage of CD45 cells. Cultures of cell prepara-
tions were tested and proved negative for bacterial and
fungal contamination.
ABMMNC implantation. Within 2 hours of the
bone marrow collection, the ABMMNCs were implanted
into the leg with CLI by means of multiple intramuscular
injections into the gastrocnemius muscle, intermetatarsal
region, and around the trophic lesions. ABMMNC injec-
tions were commenced 4 to 5 cm proximal to the obstruc-
tive lesion and continued distally in all patients. General
anesthesia was preferred if débridement was required for
ischemic ulcers and mild sedation was used for isolated
ABMMNC implantation. In eligible patients, control treat-
ment with normal saline into the less ischemic contralateral
limb was also performed during each procedure. We used
22-gauge spinal needle and a 7-cm grid to implant about
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and oblique) for a total of 54  7 sites (range, 41 to 70).
Follow-up. Clinical, operative, and follow-up data
were recorded prospectively in a computerized database.
Three (10.7%) of 28 patients were taking lipid-lowering
medication on their initial evaluation in the outpatient
clinic (Table). All patients were treated with aspirin (300
mg daily), statin (if total cholesterol concentrations were
150 mg/dL), and L-arginine (500 mg daily). Patients
were required to be on this medication regimen 6 months
before entry into the study, and the drugs used were not
changed throughout the study.
The patients were seen in the outpatient clinic every 2
weeks postoperatively for evaluation of pain scores, QOL
assessment using VascuQol scores, and trophic lesions.
Repeat digital subtraction angiography was performed
at 6-months. Six-month follow-up was completed in all
patients.
Statistical analysis. For the study to support the
working hypothesis, it needed to have the power of being
able to show significant improvements in the total healing
of the ischemic ulcer, while avoiding major or minor am-
putation, and the total relief of rest pain without the need
for analgesics. We determined from the data reported by
Tateishi-Yuyama9 and our feasibility study21 that 25 sub-
jects in treatment groups with 90% power and a P  .05
were required to be detected to have a significant clinical
improvement.
Because of the small sample size and nonnormal distri-
bution of the variables, nonparametric tests were used to
measure the differences. We performed the Friedman test
to find the differences among the groups, and theWilcoxon
signed test to find which group created these differences. In
the Wilcoxon signed-rank test, the Bonferroni adjustment
for the significance levels was used. To compare the signif-
icance of three pairs of the variables ABPI, VAS pain score,
peak walking time, and claudication onset time for baseline
and 3 and6months, we used .05/3 (.0167) significance level,
and for VascuQol scores, .05/6 (.0083) significance level for
6 different pairs of comparison. Data were analyzed using
SPSS 11.5 (SPSS Inc, Chicago, Ill) for Windows (Microsoft
Corp, Redmond, Wash).
RESULTS
Since 2000, the ratio of new patients with TAO to the
new patients with arteriosclerosis obliterans has been 1:4 at
our outpatient clinic. During the study period, 52 patients
with TAO (46 men, 6 women) were admitted to the Heart
Center at the University of Ankara; of these, 32 were
graded as Rutherford II-III, and 28 were included in the
study protocol. Four patients who were not included in the
study did not want to participate after receiving detailed
information about the possible side effects of cellular ther-
apy, and 18 patients were graded as Rutherford I and
excluded from the study. All subjects were smokers and
presented with ischemic rest pain or trophic lesions, or
both. Mean age at disease onset was 33 years (range, 20 to
45 years), and mean age at initial evaluation was 42 years(range, 25 to 54 years). The disease involved the infrapop-
liteal arteries in 28 patients (100%) and the upper extrem-
ities in 9 patients (32%) (Table).
Procedural data. The same surgical team performed
all procedures. The mean total bone marrow harvesting
time was 35.7 6.1 minutes (range, 27 to 50minutes) and
the mean total procedural time for ABMMNC implanta-
tion was 32.5 4.4 minutes (range, 22 to 39 minutes). In
each injection, approximately 2 million cells were delivered
in a volume of 1 mL. All necrotic and devitalized tissues
were eradicated with surgical debridement in 18 patients
(64.2%) with ischemic ulcers.
Safety data. No patient experienced periprocedural
complications and ABMMNC implantation was well toler-
ated. No patient received a transfusion after bone marrow
harvest. Before discharge, however, three patients (10.7%)
who were diagnosed with iron deficiency–induced hypo-
chromic microcytic anemia were treated by oral iron re-
placement therapy for 3 months. All patients with rest pain
were discharged on the second day of hospitalization as
specified by the protocol. For patients with trophic lesions,
hospital stay after ABMMNCwas 26.4 14.6 days (range,
7 to 52 days). All patients remained free of retinopathy
observed in funduscopic examinations and teratoma forma-
tion. The levels of C-reactive protein, white blood cells, and
fibrinogen at baseline and follow-up were not significantly
different.
Follow-up evaluations. Mean follow-up after
ABMMNC implantation was 16.6  7.8 months (range,
7.6 to 33.8 months), and follow-up was 100% complete. At
the last visit, spot urine in the morning was collected from
all subjects and analyzed for measurement of cotinine by
radioimmunoassay. Values were corrected for urine concen-
tration and expressed as nanograms per milliliter of urinary
creatinine. The findings suggested that self-reported smoking
status did not correlate with cotinine-indicated smoking
status. Urinary creatinine-adjusted cotinine values were
500 ng/mL in 17 patients (60.7%), although only five
patients admitted that they had restarted smoking.
None of the patients underwent major amputation,
defined as above-the-knee, below-the-knee, or hand ampu-
tation during this time period; however, toe amputation
could not be avoided in one patient who continued smoking.
Among four patients with Rutherford grade II-III who
were excluded from the study because they did not provide
informed consent, three underwent a major amputation at
1-year follow-up. The baseline mean VAS pain score was
8.2  1.2. Significant reductions in VAS scores were ob-
served in ABMMNC-implanted limbs at 3 (1.1  1.4
months; P  .0001 vs baseline) and 6 months (0.9  1.7
months; P  .0001 vs baseline), whereas control limbs did
not differ with respect to the baseline VAS scores.
ABMMNC implantation did not alter blood pressures
(mean blood pressure, from 83.4  12 to 81.6  11 mm
Hg after 6 months) but improved the ABPI from 0.52 
0.09 at baseline to 0.62 0.12 after 3 months (P .0001)
and to 0.67  0.13 after 6 months (P  .001) (Fig 1). A
change in the ABPI0.15 was achieved in eight patients at
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follow-up compared with baseline values. Improvement in
ABPI was sustained for up to 34 months. No changes in
ABPI were detected in contralateral legs injected with
saline at 3 (P  .067) and 6 months (P  .055).
In review of treadmill testing before ABMMNC im-
plantation and 3 months after, peak walking time and
claudication onset time significantly improved (P .0001),
and this improvement was maintained at 6 months (P 
.0001) (Fig 2). Three treadmill tests were terminated be-
cause of claudication pain in the control leg at 6 months.
VascuQol scores also showed significant improvement in
QOL after ABMMNC implantation at 3 months (P 
.0083), and further improvement was achieved at 6 months
(P  .0083). Additional subgroup analyses for activity,
pain, other symptoms, emotional, and social items are
presented in Fig 3.
Ischemic ulcers healed completely in 15 patients (83%)
and improved markedly in three (17%). Representative
photos are shown in Fig 4. One patient who continued to
Fig 1. Resting ankle brachial pressure indices (ABPI)  SD
were measured in 28 autologous bone marrow-mononuclear
cell (ABMMNC) implanted limbs and saline injected contralat-
eral limbs at baseline and 3 and 6 months after the procedure.
Note that ABPI 0.15 in eight patients at 3 months and in
14 patients at 6 months in ABMMNC implanted limbs. *Repre-
sents P  .0001 vs baseline. †Represents P  .001 vs 3 months).
Fig 2. Box-whisker plot summaries of values  SD for peak
walking time and claudication onset time at baseline, and 1, 3, and
6 months after autologous bone marrow-mononuclear cell im-
plantation in 28 patients. *Represents P  .0001. †P  .01 vs
baseline.smoke required toe amputation because of osteomyelitisduring follow-up. An ischemic ulcer developed in the con-
trol leg of one patient at 11 months after the procedure. Six
Fig 3. Mean  SD values for Vascular Quality of Life Question-
naire (VASCUQOL) at four time points: baseline, and 1, 3, and 6
months after autologous bone marrow-mononuclear cell implan-
tation in patients with thromboangiitis obliterans and critical limb
ischemia (n  28). *Represents P  .0083 compared with data at
baseline. †P  .0083 compared with data at fourth week. ‡P 
.0083 compared with data at 3 months.
Fig 4. Limb salvage after autologous bone marrow-derived
mononuclear cell (ABMMNC) therapy; preoperative (I, II) and
postoperative (III and IV) images of patients with ischemic ulcers.
AI, AII, A 43-year-old man presented with nonhealing left toe
ischemic ulceration. AIII, AIV, Complete healing was achieved at
80 days after cellular therapy. BI, BII, A 32-year-old man pre-
sented with nonhealing trophic lesion on the great toe. BIII, BIV,
Photos of the same patient 4 months after ABMMNC implanta-
tion. CI, C2, Nonhealing ischemic wound of the great toe after
surgical débridement in a patient who required high doses of
narcotic analgesics. CIII, CIV, Complete healing was achieved at
3 weeks and maintained at 24 months.months after the ABMMNC implantation, angiographic
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noted in 22 (78.6%) of 28 patients (2.64  0.62 in the
ABMMNC implanted limbs vs 0.30  0.01 in the con-
tralateral limbs). Representative angiograms are shown in
Fig 5.
DISCUSSION
The results of our study suggest that ABMMNC im-
plantation into ischemic limbs of patients with TAO is
associated with improved exercise performance, quality of
life, ABPI, pain control, and augmentation of collateral
formation at 24 weeks in 78% of patients. The present study
confirms that intramuscular injection of ABMMNC is safe
and feasible. This study is the first report in a large series
consisting only of TAO patients with CLI who underwent
ABMMNC implantation and comparing the results with
saline-infused control limbs. Inclusion criteria for our study
restricted treatment to patients with unilateral CLI to com-
pare multiple injections of placebo to the less ischemic
limb. Since multiple injections could also stimulate angio-
genesis by a wound-healing response to injury,22 the ques-
tion of the effect of needle punctures on angiogenesis
would be eliminated.
In animal models of ischemia, the ability of EPCs
isolated from human peripheral blood4 or bone marrow23
Fig 5. A, B, Baseline digital subtraction angiographic (DSA)
studies reveal right infrapopliteal and upper extremity involvement
of a 32-year-old man with a nonhealing right foot toe ulceration.
C. Contrast arteriogram shows only small collateral vessels in the
right calf and no vessels suitable for use in a distal bypass procedure.
D, Lower extremity DSA study confirms new collateral vessel
formation in the right limb at the 6-month follow-up after implan-
tation of autologous bone marrow-derived mononuclear cells
(ABMMNC). Note similar attenuation of the contralateral limb
(baseline vs follow-up) E, Arteriogram of a 24-year-old man
demonstrates tapering multiple vascular occlusions and corkscrew
collaterals of both lower limbs. F, Increased multiple corkscrew
collaterals around the areas of occlusion in ABMMNC-implanted
right limb at the 6-month follow-up.G,DSA of a 39-year-old man
demonstrates a tapering occlusion of the right posterior tibial
artery above the ankle. H, DSA of the same patient at 6-month
follow-up shows new collateralization in ABMMNC-implanted
right limb. *ABMMNC-implanted limb. †Saline-injected control
limb. Arrows indicate new collateral vessel formations that were
visible at ABMMNC injection sites compared with the baseline
angiography.to incorporate into sites of neovascularization was shownpreviously. Culture-expanded EPC transplantation in an
animal model of limb ischemia improved neovasculariza-
tion and blood flow recovery and reduced limb necrosis and
autoamputation by 50% compared with controls.24 Several
cell types within the bone marrow cavity appear to retain
the ability to differentiate into one or more of the cellular
components of the vascular bed and thus, in theory, might
incorporate directly into the wall of the newly formed or
remodeled vessels.25
In addition to incorporation properties, EPCs also
secrete multiple angiogenic cytokines, growth factors, and
chemokines that could facilitate arteriogenesis and inhibit
endothelial and smooth muscle cell apoptosis.25 Therapeu-
tic angiogenesis regimens that have mainly focused on the
administration of a single angiogenic agent failed to show
significant improvements in the clinical outcome.26,27
Considering the complexity of the angiogenic process,
cellular therapeutic strategies may overcome most of the
shortcomings related to single growth factor applications.
In fact, Tateishi-Yuyama et al (TACT study)9 recently dem-
onstrated improvement in transcutaneous oxygen pressure,
rest pain, and pain-free walking time after ABMMNC
intramuscular injections in 25 patients with unilateral CLI.
Those results are somewhat similar to the results of the
present study, although Tateishi-Yuyama et al recruited
patients mostly with atherosclerosis obliterans. Further-
more, they recruited 22 patients with bilateral limb isch-
emia who were randomly injected with ABMMNC in one
leg and APBMNC in the other as control.
The TACT study demonstrated that APBMNC injec-
tions were less efficient in new collateral vessel formation
compared with ABMMNC. Since then, unselected growth
factor–induced APBMNC12-15 or ABMMNC10,11,21,28,29
have been used in clinical studies for CLI with satisfactory
results. Both methods have their own advantages and pit-
falls. Potential limitations of APBMNC are the time span
necessary for peripheral blood mobilization and collection
(approximately 5 days) before implantation, possible side
effects of growth factors, and the higher costs compared
with bonemarrow aspiration. The optimal route of delivery
has not been established in the setting of CLI, either.
Direct intramuscular injections have been performed by
several groups9,10,12,13 and by us.21,29
The risk of amputation in patients with TAO was
questioned previously.30 During the mean follow-up of
91.6 months, 27% of 112 patients with TAO required one
or more of the amputations. The same study demonstrated
that only 5% of the patients had amputations after smoking
cessation, but 42% had amputations while continuing to
smoke (P  .0001). Recently, Cooper et al reported that
the risk of any amputation was 25% at 5 years, 38% at 10
years, and 46% at 20 years among 111 patients with TAO
based on the information gathered from the Mayo Clinic
registry.31 Ohta et al32 also clearly demonstrated a strong
correlation between continued smoking and limb amputa-
tion in one of the largest series of TAO evaluating the social
problems and impaired quality of life.31
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our series continued smoking after cellular therapy. Minor
amputation was only required in one patient (3.6%) during
the mean follow-up of 16.6  7.8 months. Furthermore,
striking improvement in ischemic rest pain and ABPI after
implantation of ABMMNC was gratifying and maintained
after 3 months. The clinical improvement was independent
from smoking status and patterns of smoking.
Induction of angiogenic diseases, such as proliferative
retinopathy, accelerated arteriosclerosis via proinflammatory
growth factors, enhanced restenosis, arrhythmias, teratoma
formation, and ectopic calcification are possible deleterious
effects of cellular therapy. Because of the proinflammatory
potential of ABMMNC implantation via growth factors and
cytokines, we closely monitored serum inflammatory markers
in our patient population; however, our data on C-reactive
protein, white blood cell count, fibrinogen at baseline and at
follow-up at 3 and 6 months did not show any difference.
Furthermore, repeat digital subtraction angiography at 6
months confirmed no progression of the disease or new ste-
notic lesions in both treated and control limbs.
A number ofmedications such as captopril, furosemide,
spironolactone, and cyclooxygenase-2 inhibitors have been
shown to potentially interfere with the angiogenic process.
However, there is an increasing experimental and clinical
evidence to support that pleiotropic effects of statins in-
volve improving or restoring endothelial function and de-
creasing oxidative stress and vascular inflammation.33 Al-
though patients with atherosclerosis obliterans were strictly
excluded in this series, we targeted total cholesterol concen-
trations 150 mg/dL, and 78% of patients were discharged
home on statin therapy and L-arginine aiming to balance the
orchestrating factors that play a crucial role in the fundamental
steps of stem-cell mediated angiogenesis.
Major limitations of this study are the small number of
patients enrolled and the lack of long-term follow-up,
which limit conclusion about efficacy. Second, contralateral
“control” limbs are not ideal matches for comparison with
the treated limbs. However, our intention for choosing
contralateral leg as control was to investigate the possible
angiogenic effects of mechanical punctures caused by sim-
ple needle injections. Furthermore, we are aware of the
limitations of currently available diagnostic contrast angio-
graphic studies to demonstrate angiogenesis or arteriogen-
esis especially for the vessels measuring 200 m in diam-
eter.34 We also acknowledge that flow hemodynamics,
including cardiac output, blood pressure, and heart rate can
effect distal perfusion and vessel imaging so the acquisition
of the digital subtraction arteriography images are prone to
error. However, if confirmed with advanced imaging tech-
niques such as gadolinium-enhanced magnetic resonance
angiography or 64-row multidetector computed tomogra-
phy angiography, our results may suggest that ABMMNC
implantation has a positive effect on therapeutic angiogen-
esis in patients with TAO and CLI. Finally, no safety issues
associated with ABMMNC implantation were identified
throughout the 16.6 months of mean follow-up.Wewould sincerely like to thank all the participants and
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Ayyildiz and the other members of hemapheresis team for
their outstanding technical assistance and continuing sup-
port of this research program; Tumer Corapcıoglu, Bulent
Kaya, Sadık Eryilmaz for thoughtful discussions, comments
on themanuscript, and supporting the study; Cagdas Baran
for collecting data of exceptional quality and his efforts for
patients’ care; Leyla Yigit, PhD, for her statistical review,
and Arzu Akar for proofreading of the manuscript.
AUTHOR CONTRIBUTIONS
Conception and design: SD, ARA, MA, TS, UO
Analysis and interpretation: SD, ARA, MA, TS
Data collection: SD, ARA, MA
Writing the article: SD, ARA, MA, TS
Critical revision of the article: MA, NTE, UO
Final approval of the article: SD, ARA, TS, NTE, UO
Statistical analysis: ARA, SD, MA
Obtained funding: ARA, NTE, UO
Overall responsibility: ARA
Drs Durdu and Akar contributed equally to this work.
REFERENCES
1. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl JMed
2000;343:864-9.
2. Roncon-Albuquerque R, Serrao P, Vale-Pereira R, Costa-Lima J,
Roncon-Albuquerque R Jr. Plasma catecholamines in Buerger’s
disease: effects of cigarette smoking and surgical sympathectomy.
Eur J Vasc Endovasc Surg 2002;24:338-43.
3. Akar AR, Durdu S, Corapcioglu T, Ozyurda U. Regenerative medicine
for cardiovascular disorders. New milestones: adult stem cells. Artif
Organs 2006;30:213-32.
4. Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, et al.
Isolation of putative progenitor endothelial cells for angiogenesis.
Science 1997;275:964-7.
5. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobiliza-
tion, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003;
23:1185-9.
6. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation
for organ vascularization and regeneration. Nat Med 2003;9:702-12.
7. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal
vasculogenesis. Am J Physiol Cell Physiol 2004;287:C572-9.
8. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic
strategies for postnatal neovascularization. J Clin Invest 1999;103:
1231-6.
9. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S,
Masaki H, et al. Therapeutic angiogenesis for patients with limb isch-
aemia by autologous transplantation of bone-marrow cells: a pilot study
and a randomised controlled trial. Lancet 2002;360:427-35.
10. Higashi Y, Kimura M, Hara K, Noma K, Jitsuiki D, Nakagawa K, et al.
Autologous bone-marrow mononuclear cell implantation improves
endothelium-dependent vasodilation in patients with limb ischemia.
Circulation 2004;109:1215-8.
11. Saigawa T, Kato K, Ozawa T, Toba K, Makiyama Y, Minagawa S, et al.
Clinical application of bone marrow implantation in patients with
arteriosclerosis obliterans, and the association between efficacy and the
number of implanted bone marrow cells. Circ J 2004;68:1189-93.
12. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous
transplantation of granulocyte colony-stimulating factor-mobilized pe-
ripheral blood mononuclear cells improves critical limb ischemia in
diabetes. Diabetes Care 2005;28:2155-60.
13. Huang PP, Li SZ, Han MZ, Xiao ZJ, Yang RC, Qiu LG, et al.
Autologous transplantation of peripheral blood stem cells as an effective
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 4 Durdu et al 739therapeutic approach for severe arteriosclerosis obliterans of lower
extremities. Thromb Haemost 2004;91:606-9.
14. Ishida A, Ohya Y, Sakuda H, Ohshiro K, Higashiuesato Y, NakaemaM,
et al. Autologous peripheral blood mononuclear cell implantation for
patients with peripheral arterial disease improves limb ischemia. Circ J
2005;69:1260-5.
15. Kawamura A, Horie T, Tsuda I, Ikeda A, Egawa H, Imamura E, et al.
Prevention of limb amputation in patients with limbs ulcers by autolo-
gous peripheral blood mononuclear cell implantation. Ther Apher Dial
2005;9:59-63.
16. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reports dealing with lower ex-
tremity ischemia: revised version. J Vasc Surg 1997;26:517-38.
17. Shionoya S. Diagnostic criteria of Buerger’s disease. Int J Cardiol
1998;66:S243-5.
18. Riebe D, Patterson RB, Braun CM. Comparison of two progressive
treadmill tests in patients with peripheral arterial disease. Vasc Med
2001;6:215-21.
19. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the Vascu-
lar Quality of Life Questionnaire: a new disease-specific quality of life
measure for use in lower limb ischemia. J Vasc Surg 2001;33:679-87.
20. Arslan O, Arat M, Ciftci A, Ayyildiz E, Ilhan O. Depletion of donors
erythrocytes using cell separator in major ABO mismatched allogeneic
bone marrow transplantation. Blood 2000;96(Suppl. Part 2):5152.
21. Akar AR, Durdu S, Arikbuka M, Arat M, Soydan E, Arslan O, et al.
Implantation of autologous bone marrow mononuclear cells for
Buerger’s disease with retractable limb ischaemia. BoneMarrow Trans-
plant 2005;35(Suppl. 2):S76.
22. Chu VF, Giaid A, Kuang JQ, McGinn AN, Li CM, Pelletier MP, et al.
Thoracic Surgery Directors Association Award. Angiogenesis in transmyo-
cardial revascularization: comparison of laser versus mechanical punctures.
Ann Thorac Surg 1999;68:301-7.
23. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM.
Origin of endothelial progenitors in human postnatal bone marrow.
J Clin Invest 2002;109:337-46.
24. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney
M, et al. Transplantation of ex vivo expanded endothelial progenitor
cells for therapeutic neovascularization. Proc Natl Acad Sci U S A
2000;97:3422-7.25. Kinnaird T, Stabile E, Burnett MS, Epstein SE. Bone-marrow-derived
cells for enhancing collateral development: mechanisms, animal data,
and initial clinical experiences. Circ Res 2004;95:354-63.
26. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. Therapeutic
interventions for enhancing collateral development by administration of
growth factors: basic principles, early results and potential hazards.
Cardiovasc Res 2001;49:532-42.
27. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO,
Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular
endothelial growth factor in peripheral arterial disease: a phase II
randomized, double-blind, controlled study of adenoviral delivery of
vascular endothelial growth factor 121 in patients with disabling inter-
mittent claudication. Circulation 2003;108:1933-8.
28. Esato K, Hamano K, Li TS, Furutani A, Seyama A, Takenaka H, et al.
Neovascularization induced by autologous bone marrow cell implanta-
tion in peripheral arterial disease. Cell Transplant 2002;11:747-52.
29. Akar AR, Durdu S, Arat M, Eren NT, Arslan O, Corapcioglu T, et al.
Therapeutic angiogenesis by autologous transplantation of bone-
marrow mononuclear cells for Buerger’s patients with retractable limb
ischaemia. Preliminary results. Turkish J Haematology 2004;21:13-21.
30. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The
changing clinical spectrum of thromboangiitis obliterans (Buerger’s
disease). Circulation 1990;82:IV3-8.
31. Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman
KV. Long-term survival and amputation risk in thrombangiitis abliter-
ans (Buerger’s disease). J Am Coll Cardiol 2004;44:2410-1.
32. Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social
consequences of Buerger disease. J Vasc Surg 2004;39:176-80.
33. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl
coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:
1712-9.
34. Takeshita S, Isshiki T, Mori H, Tanaka E, Eto K, Miyazawa Y, et al.
Use of synchrotron radiation microangiography to assess develop-
ment of small collateral arteries in a rat model of hindlimb ischemia.
Circulation 1997;95:805-8.Submitted Feb 24, 2006; accepted Jun 25, 2006.
